Would you consider trastuzumab deruxtecan as next line of therapy for patients with ERBB2 mutation positive, stage IIIB NSCLC, who progress within 6 months of chemo- radiation?

Yes, I would consider trastuzumab deruxtecan as the next line of therapy for patients with ERBB2 mutation-positive, stage IIIB NSCLC, who progress within 6 months of chemo-radiation. We typically use recurrence within one year as the time frame between completion of chemo-radiation and recurrence for determining whether the chemo-radiation should be considered a line of therapy. In this case, it meets that definition and I would consider trastuzumab deruxtecan as second line therapy. The use of second line trastuzumab deruxtecan is supported by the DESTINY-Lung01 and 02 (NCT04644237) trials.